{"ticker": {"uuid": "7e71d594-8ab6-404c-bc3a-4111b1743caf", "symbol": "ALDX", "name": "Aldeyra The", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Aldeyra Therapeutics Seeks FDA Clarification on Reproxalap NDA Meeting Minutes", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/aldeyra-therapeutics-seeks-fda-clarification-104408320.html", "source_name": "MT Newswires", "published_at": "2026-07-16T10:44:08+00:00", "published_display": "16 Jul 2026 10:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics (NASDAQ: ALDX) advances FDA dialogue on reproxalap NDA", "summary": "Aldeyra Therapeutics (NASDAQ: ALDX) reported ongoing regulatory discussions with the FDA concerning the New Drug Application (NDA) for reproxalap, intended for dry eye disease treatment. The company received minutes from a Type A meeting on July 14, 2026, and is now seeking clari", "url": "https://www.stocktitan.net/sec-filings/ALDX/8-k-aldeyra-therapeutics-inc-reports-material-event-bce0bc765233.html", "source_name": "Stock Titan", "published_at": "2026-07-15T21:13:01", "published_display": "15 Jul 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission", "summary": "Aldeyra Therapeutics plans to request a Type D meeting with the FDA to discuss a potential New Drug Application (NDA) resubmission for reproxalap, a treatment for dry eye disease. This decision follows their request for clarification on FDA minutes from a June 10, 2026 Type A mee", "url": "https://www.tradingview.com/news/tradingview:c6063fdfef5f3:0-aldeyra-therapeutics-to-seek-type-d-meeting-with-fda-on-reproxalap-nda-resubmission/", "source_name": "TradingView", "published_at": "2026-07-15T21:13:01", "published_display": "15 Jul 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq, S&P 500 Futures Rise As Nvidia GTC, Iran Tensions, Fed Meet Loom: Why META, MU, SOC, ALDX Are Also In Focus Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNRzNjOHZLOUxzWDZrcThZRmlnaU1heFphUDRudXR5ZlhqM2FnT2VGOExjQXhjb1FFcXQxWGNmYnJWVFduRmN1VC0xVi1mYkhocFlheEZ2ZktwV1Y1TmV4VW5mVG9vSEVldW9NZzNlbVRULUtfMWVRUkhzMHBJa3phY1Fvd3dUUTRrbURnVEJ3Sll2eFU5Vms2NV9KdGVuelZ4MHY4TkpWQnpqT3RhaEVZMVIwc0lNNTE5U1ZzZ1pUeGZZQ2J0ejV4RmlodTdsUQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T08:52:36+00:00", "published_display": "14 Jul 2026 08:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aldeyra Therapeutics (ALDX) Short Interest & Short Float | Updated Jul 2026", "summary": "Aldeyra Therapeutics (ALDX) saw a significant decline in short interest during June 2026, with the total number of shares sold short decreasing by 17.34% to 5.68 million shares. This represents 10.67% of the public float and a short interest ratio of 2.5 days to cover. The change", "url": "https://www.marketbeat.com/stocks/NASDAQ/ALDX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-11T00:40:06", "published_display": "11 Jul 2026 00:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQNXRfTUhOTUVoSGNJQWR5aFpUbWtzWmk5d0dzZEU2YTRSaGJSUFNwdl81T0ZVY3NUWk5VVmVjWFVCMURJNW1ISmlFWVo5QlktaV9NN3k3SHZYY2xVNnhrWG1SMC0wWDd4a083aDA5OFI2UkRXZXNVMEUtenVYSkU5bC1KSWNSTkFTSnhiVXMtZkdTdl9JR0VwY2k4QjVkQUp5RW1talZQSXg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T20:45:26+00:00", "published_display": "10 Jul 2026 20:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Aldeyra Therapeutics Inc. (ALDX) stock. It includes current stock price, financial details, and analyst ratings, noting that there are no current analyst ratings or earnings information available for ALDX. The page also features a dis", "url": "https://timothysykes.com/quote/ALDX/", "source_name": "timothysykes.com", "published_at": "2026-07-09T23:11:43", "published_display": "09 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (ALDX) securities. The investigation focuses on whether Aldeyra and its officers engaged in corporate wrongdoing, particularly for investors who bought share", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-aldeyra-therapeuti-1174496", "source_name": "ACCESS Newswire", "published_at": "2026-07-09T11:00:00", "published_display": "09 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) for alleged corporate wrongdoing. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to connect and assist ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-aldeyra-ther-1174495", "source_name": "ACCESS Newswire", "published_at": "2026-07-07T11:00:00", "published_display": "07 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did ALDX Stock Tank 70% Today?", "summary": "Aldeyra Therapeutics Inc. (ALDX) stock plummeted almost 70% after the U.S. FDA rejected its application for a dry eye drug, citing insufficient and inconsistent clinical data. The FDA noted a \"lack of substantial evidence\" and raised concerns about the reliability of positive fin", "url": "https://stocktwits.com/news-articles/markets/equity/aldx-stock-falls-fda-rejects-reproxalap-dry-eye-drug/cZ3EdcgRIXc", "source_name": "Stocktwits", "published_at": "2026-07-06T10:39:44", "published_display": "06 Jul 2026 10:39", "sentiment": "negative", "sentiment_pct": 9, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Reach Out", "summary": "Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) concerning alleged corporate wrongdoing. The firm encourages shareholders who purchased Aldeyra securities before November 3, 2023, and still h", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1174494", "source_name": "ACCESS Newswire", "published_at": "2026-07-05T11:00:00", "published_display": "05 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlight On Aldeyra Therapeutics And 2 Other Prominent Penny Stocks", "summary": "This article highlights three prominent penny stocks\u2014Aldeyra Therapeutics (ALDX), Anavex Life Sciences (AVXL), and Waterdrop (WDH)\u2014that exhibit strong balance sheets and potential for significant returns. Despite challenges like index exclusions for Aldeyra and Anavex, these comp", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aldx/aldeyra-therapeutics/news/spotlight-on-aldeyra-therapeutics-and-2-other-prominent-penn", "source_name": "Simply Wall Street", "published_at": "2026-07-03T21:40:16", "published_display": "03 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:137)", "summary": "This article provides an overview of Aldeyra Therapeutics, Inc. (TRADEGATE:137) including its financial actuals and estimates. It covers analyst price targets, historical stock prices, upcoming earnings reports, and recent financial performance metrics like earnings per share and", "url": "https://www.tradingview.com/symbols/TRADEGATE-137/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-07-03T00:09:39", "published_display": "03 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX) and its officers. The firm is encouraging Aldeyra shareholders who purchased securities before November 3, 2023, and continue to hold them, to", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1174493", "source_name": "ACCESS Newswire", "published_at": "2026-07-02T11:00:00", "published_display": "02 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aldeyra Therapeutics, Inc. (ALDX) concerning potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023,", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1174492", "source_name": "ACCESS Newswire", "published_at": "2026-06-30T20:09:33", "published_display": "30 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno", "summary": "Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who su", "url": "https://natlawreview.com/aldx-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-aldeyra-therapeutics", "source_name": "The National Law Review", "published_at": "2026-06-30T15:40:30", "published_display": "30 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Value Benchmark", "summary": "Aldeyra Therapeutics, Inc. (ALDX) has been removed from the Russell 2000 Value Benchmark. This news follows a period of significant activity for the company, including recent appointments to its board, insider share purchases, and a decline in its stock value after the FDA declin", "url": "https://www.marketscreener.com/news/aldeyra-therapeutics-inc-nasdaqcm-aldx-dropped-from-russell-2000-value-benchmark-ce7f5fdfd888f22d", "source_name": "marketscreener.com", "published_at": "2026-06-30T11:07:00", "published_display": "30 Jun 2026 11:07", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) dropped from Russell 2500 Growth Benchmark", "summary": "Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) has been removed from the Russell 2500 Growth Benchmark as of June 29, 2026. This biotechnology company develops therapies for immune-mediated and metabolic diseases, with product candidates like reproxalap for dry eye disease. The news ", "url": "https://www.marketscreener.com/news/aldeyra-therapeutics-inc-nasdaqcm-aldx-dropped-from-russell-2500-growth-benchmark-ce7f5fdfda81f025", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:25:00", "published_display": "29 Jun 2026 15:25", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell 3000E Growth Benchmark", "summary": "Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) has been removed from the Russell 3000E Growth Benchmark. This news follows a period of significant stock performance fluctuation and comes after several announcements regarding board appointments, insider share purchases, and a recent F", "url": "https://www.marketscreener.com/news/aldeyra-therapeutics-inc-nasdaqcm-aldx-dropped-from-russell-3000e-growth-benchmark-ce7f5fdeda88f120", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:12:00", "published_display": "29 Jun 2026 12:12", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Dynamic Index", "summary": "Aldeyra Therapeutics, Inc. (ALDX) has been removed from the Russell 2000 Dynamic Index. This news comes amidst other recent updates for the biotechnology company, including executive appointments, insider share purchases, and a significant setback with the U.S. FDA declining appr", "url": "https://www.marketscreener.com/news/aldeyra-therapeutics-inc-nasdaqcm-aldx-dropped-from-russell-2000-dynamic-index-ce7f5fdedf8efe27", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:28:00", "published_display": "29 Jun 2026 05:28", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 3000 Index", "summary": "Aldeyra Therapeutics, Inc. (NasdaqCM: ALDX) has been removed from the Russell 3000 Index. The biotechnology company, which focuses on immune-mediated and metabolic diseases, also recently announced the appointment of Darlene Deptula-Hicks to its Board of Directors and reported ea", "url": "https://www.marketscreener.com/news/aldeyra-therapeutics-inc-nasdaqcm-aldx-dropped-from-russell-3000-index-ce7f5fdeda8df024", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:11:11", "published_display": "29 Jun 2026 05:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "137 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Aldeyra Therapeutics, Inc. (137) based on analyst opinions. It includes financial data, past performance, and upcoming earnings information. The company's highest price on record was 13.61 EUR, and the lowest was 1.05 EUR, wit", "url": "https://www.tradingview.com/symbols/FWB-137/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T11:09:39", "published_display": "28 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (ALDX). The investigation focuses on whether the company and its officers engaged in corporate wrongdoing, specifically for investors who bought securities b", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/aldeyra-therapeutics-inc.-aldx-investigation-bronstein-gewirtz-a-1174491", "source_name": "ACCESS Newswire", "published_at": "2026-06-28T11:00:00", "published_display": "28 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALDX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Aldeyra Therapeutics, Inc. (ALDX) stock for 2027, based on analyst opinions. It includes current stock performance metrics, historical price data, financial insights, and upcoming earnings information. The content emphasizes t", "url": "https://www.tradingview.com/symbols/NASDAQ-ALDX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T06:41:27", "published_display": "27 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aldeyra Therapeutics, Inc. \u2013 NASDAQ:ALDX", "summary": "This article provides financial information for Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), specifically focusing on its \"Price to book forward\" metric. The content highlights the company's stock market presence on Nasdaq and offers a brief overview of available financial data.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALDX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:41:27", "published_display": "27 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aldeyra Therapeutics, Inc. \u2013 DUS:137", "summary": "This page from TradingView provides financial information for Aldeyra Therapeutics, Inc. (DUS:137), specifically focusing on its \"Price to book forward\" metric. The content includes navigation to various financial tools, market data, and community features, but the primary articl", "url": "https://www.tradingview.com/symbols/DUS-137/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:09:52", "published_display": "27 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Aldeyra Therapeutics, Inc. \u2013 DUS:137", "summary": "This article provides the \"Price to sales forward\" value for Aldeyra Therapeutics, Inc. (DUS:137). It indicates the financial data is currently unavailable as the market is closed with no trades recorded. The content functions as a placeholder or an unpopulated financial data pag", "url": "https://www.tradingview.com/symbols/DUS-137/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:09:39", "published_display": "26 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Aldeyra Therapeutics, Inc. \u2013 DUS:137", "summary": "This article displays the forward enterprise value to revenue for Aldeyra Therapeutics, Inc. (DUS:137). It shows that the \"Period Value\" and related \"Change\" and \"Change %\" metrics are currently empty, indicating no available data at this time. The data is provided by TradingView", "url": "https://www.tradingview.com/symbols/DUS-137/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:41:06", "published_display": "26 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALDX)", "summary": "Aldeyra Therapeutics, Inc. (ALDX) stock is currently trading at 1.83 USD, experiencing a -5.26% decrease in the past 24 hours. Analysts predict a future price range of 2.00 USD to 13.00 USD. The company's market capitalization is 108.58M USD, and it will release its next earnings", "url": "https://www.tradingview.com/symbols/NASDAQ-ALDX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:41:06", "published_display": "26 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aldeyra Therapeutics, Inc. \u2013 NASDAQ:ALDX", "summary": "This page from TradingView displays the \"Price to earnings forward\" for Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). It appears to be a financial data point without further analysis or specific values provided directly on this snippet. The content is primarily a page title within t", "url": "https://www.tradingview.com/symbols/NASDAQ-ALDX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:41:06", "published_display": "26 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Aldeyra Therapeutics, Inc. \u2013 NASDAQ:ALDX", "summary": "This article provides financial information for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), specifically focusing on its Enterprise Value to EBIT forward ratio. The content is presented within the context of a financial data platform, indicating the company's market and financial s", "url": "https://www.tradingview.com/symbols/NASDAQ-ALDX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:41:17", "published_display": "26 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics (ALDX) grants board member new stock option awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOXzczUU5nOXVkUVYxX1k5a1VwM2lUYVdEay1OWFVGS3VWUE9sZlNNV3lnNWZ1YzlSdzVTbzZaSlJROHVySkU2N0ZlTF9md2dlZUg1MDRpRHhrQkp5djUwa1A5LXdFc1FYOXFFaDRzeDZFZjAxRmxTS2VieFFCeEF2SUNmUWNTeU9oYlF6NWhhZmhYWVpfM3ZLRVVaMXZ2cDNSZTFmZ3FHUnR3b2RaWWdXV09jS0locUl3V2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSjNXbnR4QVFWYkZmU3g4cVU2ZDFlOUtXdTNySk5FSlZTa1paVjdOcnNVMnBwbGlFN09LMFFOLWVxbWxiYUJoNTdnV3Z4dzFoOTNfUDAwR1dkb2VTUUJqS2hhWllpTXVHYWs5M01UNmxsdUhwampPcGhlVnhWZzRKaDFMSndhRGZwY2tFUkoxYkktREYzQy1BWGR4Y1VrZ3pOWE54N0Y4bkdETDJK?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics CEO, President & Director Acquires 18% More Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPc2xfWExoZHU5aElMTUlydnQzaV9UblFZRE5SMHByZXFmanEyUGI5X2NPRXU0RUVpa3B2eHhJd3k4N0NZRk5vVVdhQnM1SGx3ZkRjQWoyV3VVU0xuM1VwZDY1TEJfZVRKT2hwX09VcVJvZzZJNFJlUXNRQ254bFJzSEllLUhqWEJpcEFkWjRUb1BlWThXNUl6MmlQZUFjZ0JBQkxyRzc1T19VcTZrQVhRQ3NNZjNYOFIwdjI5Y2RzVzg2Q1ZFbkhPVm1B?oc=5", "source_name": "Business Wire", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics Insider Bought Shares Worth $418,450, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/aldeyra-therapeutics-insider-bought-shares-202619169.html", "source_name": "MT Newswires", "published_at": "2026-06-05T20:26:19+00:00", "published_display": "05 Jun 2026 20:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOQUczSW8ybWVRdVBkZTE5RUkwZUlTSF9nZWVHODlBcFdSSzRvam9jR0JuYmd6dUVkTXgzOTRocGxyQkpIM1kweXBSalJDSmk4MTBJMXN0clZSc3VwdUhZdmtVUHAwMDFiTHJkeFZlRWt6SkZaY2ZQQWpsSVVuNHZMdE9sWDdYdFZZN2tKWmxPVllzVGdZUG9zTUpyeFpuV0ZOMmFOR0sxYWRqMXctQ1B2c1ljVE1tSWZKSC1mNlpn?oc=5", "source_name": "Investing.com", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment", "summary": "", "url": "https://finance.yahoo.com/m/d6b525d8-1f2f-323e-974b-98b6bff4b850/aldeyra-therapeutics-eyes-fda.html", "source_name": "MarketBeat", "published_at": "2026-06-05T01:02:14+00:00", "published_display": "05 Jun 2026 01:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aldeyra-therapeutics-participate-2026-jefferies-110100128.html", "source_name": "Business Wire", "published_at": "2026-06-02T11:01:00+00:00", "published_display": "02 Jun 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZktnVGYtTm9SbEpMTFA3YzhHY0lueEE0bDlUOGVUQ2ZKc1ViNWlmWU5lU3hrdm9YdS14c1RscDh4UWtoTXZYcndZNkVnQV9HX1RxeEFRa2txUGs0akMwQUpUbkNIWmFSWVdzMFBPdDlLQW5WRm5pNE5WZVEyTXBHZFJ1XzNaVERROXU3czlPMkk3SGVlazUzUHNETzd4M2M4?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Reiterated Misleading Claims: SueWallSt", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wJBVV95cUxNTnA1U2dueWZKaGxBUkpTUWJjdDNXN21yaXB3WXR2elZfSGJoOFAwbjFMSkgyVVhFa25RUFR1Snp4ZEN2UFozakh3dDdNX284MENOV19SYTdJSjVuQVg0WFEtMjI1djN2U1E2UzV1YllTM2NnVVFVSDdLbC1Ed3BOY0dwQzJtS0x0dVRsUjlYYXlDNFdWdDZLQ19rUWNURVJfRTQwekM4Mm1xODdkbExqU2ZlcGc5SkhDNzFBaHhlVEJfaTBaVUE5MU9nSkNvNkdDSFRNNHYxZk1pRlFFRjdhTFJ5ekpyc2RvNlB4bEk1OURIM2ZJTWpIVm1WNUJ2VDNWdW1Fd2VMRUN0VGhpcmNuUmR0R2w1YVRZMEpmV09xdGZIbXluNXJ5enYxUnJzNU50NjduQzZZTzJCNFdQT2k0T21aZ2ljR2JYZkh5Y2lQRTJyUDUtS3V2OXZrZVkzdWdKbURF?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Aldeyra Therapeutics And 2 More Promising Penny Stocks For Your Watchlist", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxORGNMVGFCejZyN0FtZDcwYzBhcEFTYWdaTUdlanFGREVxX1YyVThKbFd6TzdOeTd4UlNOMVZEbWYyTEc4MHRZeERZc05mX3FQV0JEOFhFWHRSS2JJSExFS2JaYWRfV0NoOFcwM20zTFVOd1ZkT0FKbV93U3FOQUV5cmhoT0IwNEtUaVJPOTBpaURBNXlydEJjVXctOXBIbzNvNnVpNg?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy Data - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics stock plunges 70% after third FDA rejection", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNclFEWjE0NmstNWN6cW9FUjJKcGM1RG5YUU1nU1V6ZXk0WXpYRW9PMGtmOEdJdHRUUjFhLWNJaWVwVVk0SUxkYXBrOV82SXExWEZZd0w1b2JtUDlHZi1iSVZINHlEdkNWNWk3dC1ldGZpZ2dBZjJLU1c3RlpZUVFTa25tdE16RXZUOHFzVzdIampSeVJ5YnpZaHVJZHFPYnRqYzNIZ2ZR?oc=5", "source_name": "The Business Journals", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Aldeyra's eye disorder drug, shares slump", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPZHVYaHRsUDdOdVVHcXd2V1B4b3oxN2hVY3NxbEd5X3pIYmRqazE0TWJYOHd1bFBLN1hXaW11VEJ0Tm5ZYVM5Ylhxb2FzeFh1RmFxMTBJT20wYkVGX3RocmEyVS02Z3BCQkNfQ09kbVlCZTZ0WlBQSDFlVzAxNDJjRFFfY25oRkNHSC1FLUpNMXFjNFYzR1NvYU0zdTJ6V3F3c1NJeWVMdm9PSHFCYU9PWTBKel9Id1hLd1Y4d3JSWQ?oc=5", "source_name": "Reuters", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNY2ktT2ZuejZ5OGFXX29KTHF5ZVp5S0NNSXhvMkxmZVppQ05teEQ1VEo2SzdDUnNCaGI2THUtdV9KWFQ3Rmt3d1J0VDU3bXh5bzlBQTJqcnY0WndWUW1rRm9FUXpnS2FMNjVYTTN2MS16d21zbzVPVkRXN3NVaFdSdVVPNEtHR0I1SjdDN1lNWEczSU1TTkE?oc=5", "source_name": "Market source", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxORzcxLTBrM0lWb19ESG5kTjRCU1p1ejNHQ2RVUnpsb21ySjN0aFA3YUVqS1hLenhDWHVwUnQxeFFSNFlQSjFVZzJxTFdncUt1Y21vMEp0VU5XekIzMjN2NGpEUjlkQTczMTlLbVNDRk54Szc5dlZ1WWlqV0ZFTnFMUkFzaUpfQlBRcXkwQlRHOA?oc=5", "source_name": "Market source", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-18T08:00:00+00:00", "published_display": "18 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQWmtnbEd2cHgwTngtLXgyMHpJZTJhUVdwV2Y0emNXYi0wc3dRWjFGemhWSnYzWllpYU5zQlhKSDBBWVJFNmFvSjhNbi1oUTA2ZjZuSU9sNmZIUDBCM2NiVWduVGVVakFZS0pIWm1wTjc5cXAzYWFTNVlmOVpoT0gyeWlGVGZ5WFpJWjV6dFYzNTd3bmpnR2pZVUVIa2lDb0dYSlIyblpOREVtQnd1alMwTFpDRlBRRi14TEhRMzI5cjlLVFRyNFh4TmZlamd3NTlXd2lDVVFabWUzSDJfa29aWTdmQQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-16T16:57:28+00:00", "published_display": "16 Dec 2025 16:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-27T08:00:00+00:00", "published_display": "27 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPNWFWNDNSeTJFeXdCSWtZNUplNG1jbTgya3RJNnV6TlppajFoSzJuZjFTUUdlX2xDN08wYjlWS2Z2cEFwZzBPUkUtcUFyRW1jNXJSTUVTOWVRMTZTaWxCUU1uYkhtb1lWdkdTVmFZMndTTEF1RlRvZU01YWJFR3ZFZld3RTJTZGNnZFF3U3FjTGlEU3BqX2RVMjBPTC13c0FiRm0zdklub1BYcGtud0FNbWYyQkFKUWdSbHc4RnlrVkczSmFxVGJ0RjRQNWxCZV85X1ltRDJB?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2025-07-24T07:00:00+00:00", "published_display": "24 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics faces stock plunge and potential FDA setback for reproxalap approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOQU5QQTR6NThzV3kyZ2p4NjNWRkZKQzFKdWc4bmhabllwdGF0SnNJbWEwMV9LdF9FcldkVmJXYmY3bzZYU19tNTUtUmotU3Rjc1ozcUhPakViZmhieHcwa05VN1RHNV9icUNDZHFLQThudGpTYTJzTkpvNGdSXzdYVWswWF9lQXRSeTl4YjFMM3ZONHRVcEh2S0swUng4TFRidjFjb1FDS0M5eHdDdjJVMDdiWEJ1TlZrSGJfeUJsR0x3U0dQZFJuZg?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2023-10-16T07:00:00+00:00", "published_display": "16 Oct 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Aldeyra Therapeutics Seeks FDA Clarification on Reproxalap NDA Meeting Minutes", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/aldeyra-therapeutics-seeks-fda-clarification-104408320.html", "source_name": "MT Newswires", "published_at": "2026-07-16T10:44:08+00:00", "published_display": "16 Jul 2026 10:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics (NASDAQ: ALDX) advances FDA dialogue on reproxalap NDA", "summary": "Aldeyra Therapeutics (NASDAQ: ALDX) reported ongoing regulatory discussions with the FDA concerning the New Drug Application (NDA) for reproxalap, intended for dry eye disease treatment. The company received minutes from a Type A meeting on July 14, 2026, and is now seeking clari", "url": "https://www.stocktitan.net/sec-filings/ALDX/8-k-aldeyra-therapeutics-inc-reports-material-event-bce0bc765233.html", "source_name": "Stock Titan", "published_at": "2026-07-15T21:13:01", "published_display": "15 Jul 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission", "summary": "Aldeyra Therapeutics plans to request a Type D meeting with the FDA to discuss a potential New Drug Application (NDA) resubmission for reproxalap, a treatment for dry eye disease. This decision follows their request for clarification on FDA minutes from a June 10, 2026 Type A mee", "url": "https://www.tradingview.com/news/tradingview:c6063fdfef5f3:0-aldeyra-therapeutics-to-seek-type-d-meeting-with-fda-on-reproxalap-nda-resubmission/", "source_name": "TradingView", "published_at": "2026-07-15T21:13:01", "published_display": "15 Jul 2026 21:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq, S&P 500 Futures Rise As Nvidia GTC, Iran Tensions, Fed Meet Loom: Why META, MU, SOC, ALDX Are Also In Focus Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgFBVV95cUxNRzNjOHZLOUxzWDZrcThZRmlnaU1heFphUDRudXR5ZlhqM2FnT2VGOExjQXhjb1FFcXQxWGNmYnJWVFduRmN1VC0xVi1mYkhocFlheEZ2ZktwV1Y1TmV4VW5mVG9vSEVldW9NZzNlbVRULUtfMWVRUkhzMHBJa3phY1Fvd3dUUTRrbURnVEJ3Sll2eFU5Vms2NV9KdGVuelZ4MHY4TkpWQnpqT3RhaEVZMVIwc0lNNTE5U1ZzZ1pUeGZZQ2J0ejV4RmlodTdsUQ?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-14T08:52:36+00:00", "published_display": "14 Jul 2026 08:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics (ALDX) Short Interest & Short Float | Updated Jul 2026", "summary": "Aldeyra Therapeutics (ALDX) saw a significant decline in short interest during June 2026, with the total number of shares sold short decreasing by 17.34% to 5.68 million shares. This represents 10.67% of the public float and a short interest ratio of 2.5 days to cover. The change", "url": "https://www.marketbeat.com/stocks/NASDAQ/ALDX/short-interest/", "source_name": "MarketBeat", "published_at": "2026-07-11T00:40:06", "published_display": "11 Jul 2026 00:40", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics: What Comes Next After Reproxalap's Third CRL (NASDAQ:ALDX)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQNXRfTUhOTUVoSGNJQWR5aFpUbWtzWmk5d0dzZEU2YTRSaGJSUFNwdl81T0ZVY3NUWk5VVmVjWFVCMURJNW1ISmlFWVo5QlktaV9NN3k3SHZYY2xVNnhrWG1SMC0wWDd4a083aDA5OFI2UkRXZXNVMEUtenVYSkU5bC1KSWNSTkFTSnhiVXMtZkdTdl9JR0VwY2k4QjVkQUp5RW1talZQSXg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T20:45:26+00:00", "published_display": "10 Jul 2026 20:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Aldeyra Therapeutics Inc. (ALDX) stock. It includes current stock price, financial details, and analyst ratings, noting that there are no current analyst ratings or earnings information available for ALDX. The page also features a dis", "url": "https://timothysykes.com/quote/ALDX/", "source_name": "timothysykes.com", "published_at": "2026-07-09T23:11:43", "published_display": "09 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (ALDX) securities. The investigation focuses on whether Aldeyra and its officers engaged in corporate wrongdoing, particularly for investors who bought share", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-encourages-aldeyra-therapeuti-1174496", "source_name": "ACCESS Newswire", "published_at": "2026-07-09T11:00:00", "published_display": "09 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) for alleged corporate wrongdoing. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to connect and assist ", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-aldeyra-ther-1174495", "source_name": "ACCESS Newswire", "published_at": "2026-07-07T11:00:00", "published_display": "07 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did ALDX Stock Tank 70% Today?", "summary": "Aldeyra Therapeutics Inc. (ALDX) stock plummeted almost 70% after the U.S. FDA rejected its application for a dry eye drug, citing insufficient and inconsistent clinical data. The FDA noted a \"lack of substantial evidence\" and raised concerns about the reliability of positive fin", "url": "https://stocktwits.com/news-articles/markets/equity/aldx-stock-falls-fda-rejects-reproxalap-dry-eye-drug/cZ3EdcgRIXc", "source_name": "Stocktwits", "published_at": "2026-07-06T10:39:44", "published_display": "06 Jul 2026 10:39", "sentiment": "negative", "sentiment_pct": 9, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Reach Out", "summary": "Bronstein, Gewirtz & Grossman, LLC has initiated an investigation into potential claims against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) concerning alleged corporate wrongdoing. The firm encourages shareholders who purchased Aldeyra securities before November 3, 2023, and still h", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-initiates-an-investigation-in-1174494", "source_name": "ACCESS Newswire", "published_at": "2026-07-05T11:00:00", "published_display": "05 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Spotlight On Aldeyra Therapeutics And 2 Other Prominent Penny Stocks", "summary": "This article highlights three prominent penny stocks\u2014Aldeyra Therapeutics (ALDX), Anavex Life Sciences (AVXL), and Waterdrop (WDH)\u2014that exhibit strong balance sheets and potential for significant returns. Despite challenges like index exclusions for Aldeyra and Anavex, these comp", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-aldx/aldeyra-therapeutics/news/spotlight-on-aldeyra-therapeutics-and-2-other-prominent-penn", "source_name": "Simply Wall Street", "published_at": "2026-07-03T21:40:16", "published_display": "03 Jul 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc. Actuals & Estimates (TRADEGATE:137)", "summary": "This article provides an overview of Aldeyra Therapeutics, Inc. (TRADEGATE:137) including its financial actuals and estimates. It covers analyst price targets, historical stock prices, upcoming earnings reports, and recent financial performance metrics like earnings per share and", "url": "https://www.tradingview.com/symbols/TRADEGATE-137/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-07-03T00:09:39", "published_display": "03 Jul 2026 00:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Shareholders to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX) and its officers. The firm is encouraging Aldeyra shareholders who purchased securities before November 3, 2023, and continue to hold them, to", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1174493", "source_name": "ACCESS Newswire", "published_at": "2026-07-02T11:00:00", "published_display": "02 Jul 2026 11:00", "sentiment": "negative", "sentiment_pct": 30, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aldeyra Therapeutics, Inc. (ALDX) concerning potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023,", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-announces-an-investigation-ag-1174492", "source_name": "ACCESS Newswire", "published_at": "2026-06-30T20:09:33", "published_display": "30 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 9, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALDX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno", "summary": "Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who su", "url": "https://natlawreview.com/aldx-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-aldeyra-therapeutics", "source_name": "The National Law Review", "published_at": "2026-06-30T15:40:30", "published_display": "30 Jun 2026 15:40", "sentiment": "negative", "sentiment_pct": 13, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Value Benchmark", "summary": "Aldeyra Therapeutics, Inc. (ALDX) has been removed from the Russell 2000 Value Benchmark. This news follows a period of significant activity for the company, including recent appointments to its board, insider share purchases, and a decline in its stock value after the FDA declin", "url": "https://www.marketscreener.com/news/aldeyra-therapeutics-inc-nasdaqcm-aldx-dropped-from-russell-2000-value-benchmark-ce7f5fdfd888f22d", "source_name": "marketscreener.com", "published_at": "2026-06-30T11:07:00", "published_display": "30 Jun 2026 11:07", "sentiment": "negative", "sentiment_pct": 31, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) dropped from Russell 2500 Growth Benchmark", "summary": "Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) has been removed from the Russell 2500 Growth Benchmark as of June 29, 2026. This biotechnology company develops therapies for immune-mediated and metabolic diseases, with product candidates like reproxalap for dry eye disease. The news ", "url": "https://www.marketscreener.com/news/aldeyra-therapeutics-inc-nasdaqcm-aldx-dropped-from-russell-2500-growth-benchmark-ce7f5fdfda81f025", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:25:00", "published_display": "29 Jun 2026 15:25", "sentiment": "negative", "sentiment_pct": 20, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc.(NasdaqCM:ALDX) dropped from Russell 3000E Growth Benchmark", "summary": "Aldeyra Therapeutics, Inc. (NasdaqCM:ALDX) has been removed from the Russell 3000E Growth Benchmark. This news follows a period of significant stock performance fluctuation and comes after several announcements regarding board appointments, insider share purchases, and a recent F", "url": "https://www.marketscreener.com/news/aldeyra-therapeutics-inc-nasdaqcm-aldx-dropped-from-russell-3000e-growth-benchmark-ce7f5fdeda88f120", "source_name": "marketscreener.com", "published_at": "2026-06-29T12:12:00", "published_display": "29 Jun 2026 12:12", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 2000 Dynamic Index", "summary": "Aldeyra Therapeutics, Inc. (ALDX) has been removed from the Russell 2000 Dynamic Index. This news comes amidst other recent updates for the biotechnology company, including executive appointments, insider share purchases, and a significant setback with the U.S. FDA declining appr", "url": "https://www.marketscreener.com/news/aldeyra-therapeutics-inc-nasdaqcm-aldx-dropped-from-russell-2000-dynamic-index-ce7f5fdedf8efe27", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:28:00", "published_display": "29 Jun 2026 05:28", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc.(NasdaqCM: ALDX) dropped from Russell 3000 Index", "summary": "Aldeyra Therapeutics, Inc. (NasdaqCM: ALDX) has been removed from the Russell 3000 Index. The biotechnology company, which focuses on immune-mediated and metabolic diseases, also recently announced the appointment of Darlene Deptula-Hicks to its Board of Directors and reported ea", "url": "https://www.marketscreener.com/news/aldeyra-therapeutics-inc-nasdaqcm-aldx-dropped-from-russell-3000-index-ce7f5fdeda8df024", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T05:11:11", "published_display": "29 Jun 2026 05:11", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "137 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Aldeyra Therapeutics, Inc. (137) based on analyst opinions. It includes financial data, past performance, and upcoming earnings information. The company's highest price on record was 13.61 EUR, and the lowest was 1.05 EUR, wit", "url": "https://www.tradingview.com/symbols/FWB-137/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-28T11:09:39", "published_display": "28 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation", "summary": "Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (ALDX). The investigation focuses on whether the company and its officers engaged in corporate wrongdoing, specifically for investors who bought securities b", "url": "https://www.accessnewswire.com/newsroom/en/business-and-professional-services/aldeyra-therapeutics-inc.-aldx-investigation-bronstein-gewirtz-a-1174491", "source_name": "ACCESS Newswire", "published_at": "2026-06-28T11:00:00", "published_display": "28 Jun 2026 11:00", "sentiment": "negative", "sentiment_pct": 28, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALDX Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Aldeyra Therapeutics, Inc. (ALDX) stock for 2027, based on analyst opinions. It includes current stock performance metrics, historical price data, financial insights, and upcoming earnings information. The content emphasizes t", "url": "https://www.tradingview.com/symbols/NASDAQ-ALDX/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-27T06:41:27", "published_display": "27 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aldeyra Therapeutics, Inc. \u2013 NASDAQ:ALDX", "summary": "This article provides financial information for Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), specifically focusing on its \"Price to book forward\" metric. The content highlights the company's stock market presence on Nasdaq and offers a brief overview of available financial data.", "url": "https://www.tradingview.com/symbols/NASDAQ-ALDX/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T06:41:27", "published_display": "27 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Aldeyra Therapeutics, Inc. \u2013 DUS:137", "summary": "This page from TradingView provides financial information for Aldeyra Therapeutics, Inc. (DUS:137), specifically focusing on its \"Price to book forward\" metric. The content includes navigation to various financial tools, market data, and community features, but the primary articl", "url": "https://www.tradingview.com/symbols/DUS-137/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T04:09:52", "published_display": "27 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Aldeyra Therapeutics, Inc. \u2013 DUS:137", "summary": "This article provides the \"Price to sales forward\" value for Aldeyra Therapeutics, Inc. (DUS:137). It indicates the financial data is currently unavailable as the market is closed with no trades recorded. The content functions as a placeholder or an unpopulated financial data pag", "url": "https://www.tradingview.com/symbols/DUS-137/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T19:09:39", "published_display": "26 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Aldeyra Therapeutics, Inc. \u2013 DUS:137", "summary": "This article displays the forward enterprise value to revenue for Aldeyra Therapeutics, Inc. (DUS:137). It shows that the \"Period Value\" and related \"Change\" and \"Change %\" metrics are currently empty, indicating no available data at this time. The data is provided by TradingView", "url": "https://www.tradingview.com/symbols/DUS-137/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T15:41:06", "published_display": "26 Jun 2026 15:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics, Inc. Actuals & Estimates (NASDAQ:ALDX)", "summary": "Aldeyra Therapeutics, Inc. (ALDX) stock is currently trading at 1.83 USD, experiencing a -5.26% decrease in the past 24 hours. Analysts predict a future price range of 2.00 USD to 13.00 USD. The company's market capitalization is 108.58M USD, and it will release its next earnings", "url": "https://www.tradingview.com/symbols/NASDAQ-ALDX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:41:06", "published_display": "26 Jun 2026 14:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Aldeyra Therapeutics, Inc. \u2013 NASDAQ:ALDX", "summary": "This page from TradingView displays the \"Price to earnings forward\" for Aldeyra Therapeutics, Inc. (NASDAQ: ALDX). It appears to be a financial data point without further analysis or specific values provided directly on this snippet. The content is primarily a page title within t", "url": "https://www.tradingview.com/symbols/NASDAQ-ALDX/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T08:41:06", "published_display": "26 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Aldeyra Therapeutics, Inc. \u2013 NASDAQ:ALDX", "summary": "This article provides financial information for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), specifically focusing on its Enterprise Value to EBIT forward ratio. The content is presented within the context of a financial data platform, indicating the company's market and financial s", "url": "https://www.tradingview.com/symbols/NASDAQ-ALDX/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:41:17", "published_display": "26 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics (ALDX) grants board member new stock option awards", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxOXzczUU5nOXVkUVYxX1k5a1VwM2lUYVdEay1OWFVGS3VWUE9sZlNNV3lnNWZ1YzlSdzVTbzZaSlJROHVySkU2N0ZlTF9md2dlZUg1MDRpRHhrQkp5djUwa1A5LXdFc1FYOXFFaDRzeDZFZjAxRmxTS2VieFFCeEF2SUNmUWNTeU9oYlF6NWhhZmhYWVpfM3ZLRVVaMXZ2cDNSZTFmZ3FHUnR3b2RaWWdXV09jS0locUl3V2c?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CEO, President & Director of Aldeyra Therapeutics Picks Up 18% More Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNSjNXbnR4QVFWYkZmU3g4cVU2ZDFlOUtXdTNySk5FSlZTa1paVjdOcnNVMnBwbGlFN09LMFFOLWVxbWxiYUJoNTdnV3Z4dzFoOTNfUDAwR1dkb2VTUUJqS2hhWllpTXVHYWs5M01UNmxsdUhwampPcGhlVnhWZzRKaDFMSndhRGZwY2tFUkoxYkktREYzQy1BWGR4Y1VrZ3pOWE54N0Y4bkdETDJK?oc=5", "source_name": "Market source", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics CEO, President & Director Acquires 18% More Stock", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPc2xfWExoZHU5aElMTUlydnQzaV9UblFZRE5SMHByZXFmanEyUGI5X2NPRXU0RUVpa3B2eHhJd3k4N0NZRk5vVVdhQnM1SGx3ZkRjQWoyV3VVU0xuM1VwZDY1TEJfZVRKT2hwX09VcVJvZzZJNFJlUXNRQ254bFJzSEllLUhqWEJpcEFkWjRUb1BlWThXNUl6MmlQZUFjZ0JBQkxyRzc1T19VcTZrQVhRQ3NNZjNYOFIwdjI5Y2RzVzg2Q1ZFbkhPVm1B?oc=5", "source_name": "Business Wire", "published_at": "2026-06-09T07:00:00+00:00", "published_display": "09 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics Insider Bought Shares Worth $418,450, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/aldeyra-therapeutics-insider-bought-shares-202619169.html", "source_name": "MT Newswires", "published_at": "2026-06-05T20:26:19+00:00", "published_display": "05 Jun 2026 20:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics CEO Todd Brady buys $418,450 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOQUczSW8ybWVRdVBkZTE5RUkwZUlTSF9nZWVHODlBcFdSSzRvam9jR0JuYmd6dUVkTXgzOTRocGxyQkpIM1kweXBSalJDSmk4MTBJMXN0clZSc3VwdUhZdmtVUHAwMDFiTHJkeFZlRWt6SkZaY2ZQQWpsSVVuNHZMdE9sWDdYdFZZN2tKWmxPVllzVGdZUG9zTUpyeFpuV0ZOMmFOR0sxYWRqMXctQ1B2c1ljVE1tSWZKSC1mNlpn?oc=5", "source_name": "Investing.com", "published_at": "2026-06-05T07:00:00+00:00", "published_display": "05 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment", "summary": "", "url": "https://finance.yahoo.com/m/d6b525d8-1f2f-323e-974b-98b6bff4b850/aldeyra-therapeutics-eyes-fda.html", "source_name": "MarketBeat", "published_at": "2026-06-05T01:02:14+00:00", "published_display": "05 Jun 2026 01:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/aldeyra-therapeutics-participate-2026-jefferies-110100128.html", "source_name": "Business Wire", "published_at": "2026-06-02T11:01:00+00:00", "published_display": "02 Jun 2026 11:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Pleasing Signs As A Number Of Insiders Buy Aldeyra Therapeutics Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOZktnVGYtTm9SbEpMTFA3YzhHY0lueEE0bDlUOGVUQ2ZKc1ViNWlmWU5lU3hrdm9YdS14c1RscDh4UWtoTXZYcndZNkVnQV9HX1RxeEFRa2txUGs0akMwQUpUbkNIWmFSWVdzMFBPdDlLQW5WRm5pNE5WZVEyTXBHZFJ1XzNaVERROXU3czlPMkk3SGVlazUzUHNETzd4M2M4?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALDX Investor Alert: Aldeyra Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Reiterated Misleading Claims: SueWallSt", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wJBVV95cUxNTnA1U2dueWZKaGxBUkpTUWJjdDNXN21yaXB3WXR2elZfSGJoOFAwbjFMSkgyVVhFa25RUFR1Snp4ZEN2UFozakh3dDdNX284MENOV19SYTdJSjVuQVg0WFEtMjI1djN2U1E2UzV1YllTM2NnVVFVSDdLbC1Ed3BOY0dwQzJtS0x0dVRsUjlYYXlDNFdWdDZLQ19rUWNURVJfRTQwekM4Mm1xODdkbExqU2ZlcGc5SkhDNzFBaHhlVEJfaTBaVUE5MU9nSkNvNkdDSFRNNHYxZk1pRlFFRjdhTFJ5ekpyc2RvNlB4bEk1OURIM2ZJTWpIVm1WNUJ2VDNWdW1Fd2VMRUN0VGhpcmNuUmR0R2w1YVRZMEpmV09xdGZIbXluNXJ5enYxUnJzNU50NjduQzZZTzJCNFdQT2k0T21aZ2ljR2JYZkh5Y2lQRTJyUDUtS3V2OXZrZVkzdWdKbURF?oc=5", "source_name": "PR Newswire", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics And 2 More Promising Penny Stocks For Your Watchlist", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxORGNMVGFCejZyN0FtZDcwYzBhcEFTYWdaTUdlanFGREVxX1YyVThKbFd6TzdOeTd4UlNOMVZEbWYyTEc4MHRZeERZc05mX3FQV0JEOFhFWHRSS2JJSExFS2JaYWRfV0NoOFcwM20zTFVOd1ZkT0FKbV93U3FOQUV5cmhoT0IwNEtUaVJPOTBpaURBNXlydEJjVXctOXBIbzNvNnVpNg?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics (ALDX) Is Down 75.2% After FDA Rebuffs Dry Eye Drug Efficacy Data - Has The Bull Case Changed?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics stock plunges 70% after third FDA rejection", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNclFEWjE0NmstNWN6cW9FUjJKcGM1RG5YUU1nU1V6ZXk0WXpYRW9PMGtmOEdJdHRUUjFhLWNJaWVwVVk0SUxkYXBrOV82SXExWEZZd0w1b2JtUDlHZi1iSVZINHlEdkNWNWk3dC1ldGZpZ2dBZjJLU1c3RlpZUVFTa25tdE16RXZUOHFzVzdIampSeVJ5YnpZaHVJZHFPYnRqYzNIZ2ZR?oc=5", "source_name": "The Business Journals", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "US FDA declines to approve Aldeyra's eye disorder drug, shares slump", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPZHVYaHRsUDdOdVVHcXd2V1B4b3oxN2hVY3NxbEd5X3pIYmRqazE0TWJYOHd1bFBLN1hXaW11VEJ0Tm5ZYVM5Ylhxb2FzeFh1RmFxMTBJT20wYkVGX3RocmEyVS02Z3BCQkNfQ09kbVlCZTZ0WlBQSDFlVzAxNDJjRFFfY25oRkNHSC1FLUpNMXFjNFYzR1NvYU0zdTJ6V3F3c1NJeWVMdm9PSHFCYU9PWTBKel9Id1hLd1Y4d3JSWQ?oc=5", "source_name": "Reuters", "published_at": "2026-03-17T07:00:00+00:00", "published_display": "17 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxNY2ktT2ZuejZ5OGFXX29KTHF5ZVp5S0NNSXhvMkxmZVppQ05teEQ1VEo2SzdDUnNCaGI2THUtdV9KWFQ3Rmt3d1J0VDU3bXh5bzlBQTJqcnY0WndWUW1rRm9FUXpnS2FMNjVYTTN2MS16d21zbzVPVkRXN3NVaFdSdVVPNEtHR0I1SjdDN1lNWEczSU1TTkE?oc=5", "source_name": "Market source", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Aldeyra Therapeutics (ALDX) Have the Potential to Rally 79.28% as Wall Street Analysts Expect?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxORzcxLTBrM0lWb19ESG5kTjRCU1p1ejNHQ2RVUnpsb21ySjN0aFA3YUVqS1hLenhDWHVwUnQxeFFSNFlQSjFVZzJxTFdncUt1Y21vMEp0VU5XekIzMjN2NGpEUjlkQTczMTlLbVNDRk54Szc5dlZ1WWlqV0ZFTnFMUkFzaUpfQlBRcXkwQlRHOA?oc=5", "source_name": "Market source", "published_at": "2026-02-19T08:00:00+00:00", "published_display": "19 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Following a 4.3% decline over last year, recent gains may please Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) institutional owners", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-18T08:00:00+00:00", "published_display": "18 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Aldeyra Therapeutics Stock Surging After FDA Delayed Its Dry Eye Drug Decision?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQWmtnbEd2cHgwTngtLXgyMHpJZTJhUVdwV2Y0emNXYi0wc3dRWjFGemhWSnYzWllpYU5zQlhKSDBBWVJFNmFvSjhNbi1oUTA2ZjZuSU9sNmZIUDBCM2NiVWduVGVVakFZS0pIWm1wTjc5cXAzYWFTNVlmOVpoT0gyeWlGVGZ5WFpJWjV6dFYzNTd3bmpnR2pZVUVIa2lDb0dYSlIyblpOREVtQnd1alMwTFpDRlBRRi14TEhRMzI5cjlLVFRyNFh4TmZlamd3NTlXd2lDVVFabWUzSDJfa29aWTdmQQ?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-16T16:57:28+00:00", "published_display": "16 Dec 2025 16:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Aldeyra Therapeutics (NASDAQ:ALDX) Have A Healthy Balance Sheet?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-11-27T08:00:00+00:00", "published_display": "27 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxPNWFWNDNSeTJFeXdCSWtZNUplNG1jbTgya3RJNnV6TlppajFoSzJuZjFTUUdlX2xDN08wYjlWS2Z2cEFwZzBPUkUtcUFyRW1jNXJSTUVTOWVRMTZTaWxCUU1uYkhtb1lWdkdTVmFZMndTTEF1RlRvZU01YWJFR3ZFZld3RTJTZGNnZFF3U3FjTGlEU3BqX2RVMjBPTC13c0FiRm0zdklub1BYcGtud0FNbWYyQkFKUWdSbHc4RnlrVkczSmFxVGJ0RjRQNWxCZV85X1ltRDJB?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2025-07-24T07:00:00+00:00", "published_display": "24 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Aldeyra Therapeutics faces stock plunge and potential FDA setback for reproxalap approval", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOQU5QQTR6NThzV3kyZ2p4NjNWRkZKQzFKdWc4bmhabllwdGF0SnNJbWEwMV9LdF9FcldkVmJXYmY3bzZYU19tNTUtUmotU3Rjc1ozcUhPakViZmhieHcwa05VN1RHNV9icUNDZHFLQThudGpTYTJzTkpvNGdSXzdYVWswWF9lQXRSeTl4YjFMM3ZONHRVcEh2S0swUng4TFRidjFjb1FDS0M5eHdDdjJVMDdiWEJ1TlZrSGJfeUJsR0x3U0dQZFJuZg?oc=5", "source_name": "Ophthalmology Times Europe", "published_at": "2023-10-16T07:00:00+00:00", "published_display": "16 Oct 2023 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 105, "total_relevant": 60, "sentiment_summary": {"positive": 3, "negative": 17, "neutral": 40, "score": 41, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 20.5, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 4.95, "count": 9}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 3, "negative_events": 17}, "market_context": {"has_market_context": true, "latest_close": 2.07, "latest_week": "2026-07-10", "one_week_move": -8.8, "four_week_move": 17.6, "twelve_week_move": 15.0, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.567686, "market_dynamics_buy_signal": false, "relative_strength": -56.945403, "fair_value_gap": -51.9, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 53.7758, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-8.8% over one week, +17.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 70, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 12}, {"label": "Market source", "count": 10}, {"label": "ACCESS Newswire", "count": 6}, {"label": "simplywall.st", "count": 6}, {"label": "Stocktwits", "count": 3}, {"label": "www.marketscreener.com", "count": 3}, {"label": "MT Newswires", "count": 2}, {"label": "Stock Titan", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 13}, {"label": "Regulatory and legal", "count": 9}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "41/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-8.8% over one week, +17.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Aldeyra Therapeutics Seeks FDA Clarification on Reproxalap NDA Meeting Minutes"}], "updated_at": "2026-07-16T14:30:36.012540+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}